no code implementations • 20 Feb 2024 • Catalina Mourgues-Codern, David Benrimoh, Jay Gandhi, Emily A. Farina, Raina Vin, Tihare Zamorano, Deven Parekh, Ashok Malla, Ridha Joober, Martin Lepage, Srividya N. Iyer, Jean Addington, Carrie E. Bearden, Kristin S. Cadenhead, Barbara Cornblatt, Matcheri Keshavan, William S. Stone, Daniel H. Mathalon, Diana O. Perkins, Elaine F. Walker, Tyrone D. Cannon, Scott W. Woods, Jai L. Shah, Albert R. Powers
In all three samples, participants were more likely to report the onset of delusion-spectrum symptoms prior to hallucination-spectrum symptoms (odds ratios (OR): NAPLS 2 = 4. 09; NAPLS 3 = 4. 14; PEPP, Z = 7. 01, P < 0. 001) and to present with only delusions compared to only hallucinations (OR: NAPLS 2 = 5. 6; NAPLS 3 = 11. 11; PEPP = 42. 75).
no code implementations • 6 Jan 2020 • Haleh Falakshahi, Victor M. Vergara, Jingyu Liu, Daniel H. Mathalon, Judith M. Ford, James Voyvodic, Bryon A. Mueller, Aysenil Belger, Sarah McEwen, Steven G. Potkin, Adrian Preda, Hooman Rokham, Jing Sui, Jessica A. Turner, Sergey Plis, Vince D. Calhoun
Through simulation and real data, we show our approach reveals important information about disease-related network disruptions that are missed with a focus on a single modality.